Characteristic | Number of patients (%) (n = 86) |
---|---|
Age, yr | Â |
   <50 | 33 (38.4%) |
   ≥50 | 53 (61.6%) |
T | Â |
   1 | 35 (40.7%) |
   2 | 46 (53.5%) |
   3 | 4 (4.6%) |
   4 | 1 (1.2%) |
N | Â |
   N+ | 51 (59.3%) |
   N- | 35 (40.7%) |
SBR | Â |
   2 | 36 (42.3%) |
   3 | 49 (57.7%) |
   Missing | 1 |
Hormone receptor status | Â |
   ER |  |
ER- | 60 (69.8%) |
ER+ | 26 (30.2%) |
   PR |  |
PR- | 44 (51.2%) |
PR+ | 42 (48.8%) |
   ER/PR |  |
ER-/PR- | 42 (48.9%) |
ER-/PR+ | 18 (20.9%) |
ER+/PR- | 2 (2.3%) |
ER+/PR+ | 24 (27.9%) |
Treatment | Â |
   Chemotherapy |  |
Anthracyclines | 42 (48.8%) |
Anthracyclines and taxanes | 26 (30.2%) |
No chemotherapy | 18 (21.0%) |
   Radiation therapy | 86 (100.0%) |
   Antihormone therapy | 34 (39.5%) |
   Trastuzumab | 20 (23.3%) |
Outcomes | Â |
Recurrence | 25 (29.1%) |
Death | 17 (20.0%) |